Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Regeneron Pharmaceuticals, Inc. (REGN : NSDQ)
 
 • Company Description   
Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

Number of Employees: 10,368

 
 • Price / Volume Information   
Yesterday's Closing Price: $655.01 Daily Weekly Monthly
20 Day Moving Average: 635,080 shares
Shares Outstanding: 108.54 (millions)
Market Capitalization: $71,094.31 (millions)
Beta: 0.25
52 Week High: $747.42
52 Week Low: $492.13
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.43% -0.76%
12 Week 6.48% 15.54%
Year To Date 3.72% 23.34%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
777 OLD SAW MILL RIVER ROAD
-
TARRYTOWN,NY 10591
USA
ph: 914-847-7000
fax: 914-347-2113
invest@regeneron.com http://www.regeneron.com
 
 • General Corporate Information   
Officers
Leonard S. Schleifer - President; Chief Executive Officer and Director
P. Roy Vagelos - Chairman
George D. Yancopoulos - President; Chief Scientific Officer and Director
Robert E. Landry - Executive Vice President; Finance and Chief Financ
Christopher R. Fenimore - Senior Vice President; Controller

Peer Information
Regeneron Pharmaceuticals, Inc. (CORR.)
Regeneron Pharmaceuticals, Inc. (RSPI)
Regeneron Pharmaceuticals, Inc. (CGXP)
Regeneron Pharmaceuticals, Inc. (BGEN)
Regeneron Pharmaceuticals, Inc. (GTBP)
Regeneron Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75886F107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 108.54
Most Recent Split Date: (:1)
Beta: 0.25
Market Capitalization: $71,094.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $9.90 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $40.26 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 13.00% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 16.27
Trailing 12 Months: 8.34
PEG Ratio: 1.25
Price Ratios
Price/Book: 3.57
Price/Cash Flow: 8.10
Price / Sales: 4.31
EPS Growth
vs. Year Ago Period: 13.88%
vs. Previous Quarter: -51.56%
Sales Growth
vs. Year Ago Period: 17.26%
vs. Previous Quarter: -40.12%
ROE
03/31/22 - 50.10
12/31/21 - 55.11
09/30/21 - 50.38
ROA
03/31/22 - 36.73
12/31/21 - 39.38
09/30/21 - 34.84
Current Ratio
03/31/22 - 4.76
12/31/21 - 3.56
09/30/21 - 3.71
Quick Ratio
03/31/22 - 4.09
12/31/21 - 3.07
09/30/21 - 3.16
Operating Margin
03/31/22 - 53.92
12/31/21 - 54.12
09/30/21 - 51.51
Net Margin
03/31/22 - 48.06
12/31/21 - 50.24
09/30/21 - 51.65
Pre-Tax Margin
03/31/22 - 55.33
12/31/21 - 58.03
09/30/21 - 59.42
Book Value
03/31/22 - 183.48
12/31/21 - 172.92
09/30/21 - 160.48
Inventory Turnover
03/31/22 - 1.27
12/31/21 - 1.20
09/30/21 - 0.89
Debt-to-Equity
03/31/22 - 0.14
12/31/21 - 0.11
09/30/21 - 0.11
Debt-to-Capital
03/31/22 - 11.94
12/31/21 - 9.54
09/30/21 - 10.29
 

Powered by Zacks Investment Research ©